Aseptic Manufacturing of Parenteral Drug Products
Aseptic drug manufacturing of parenteral drug products
With more than 30 years of experience in the development of parenteral drug products, we are able to support your programs from candidate development through clinical trial manufacturing via aseptic filtration techniques. Our innovative approach enables rapid development and manufacturing of sterile solution formulations for parenteral administration, with a strong emphasis on environmental and process controls to ensure the safety of your therapy.
Customized services for manufacturing your therapy
Parenteral drug products, which include intravenous (IV), subcutaneous (SC), or intramuscular (IM) routes of administration, require careful planning, thoroughly trained personnel, and dedicated facilities to ensure patient safety. At our state-of-the-art facilities, we have the expertise to develop, pharmacy compound, manufacture, test, release, and supply a range of formulations (IV, SC, and IM administration) for a variety of clinical study types, including first-in-human (FIH) healthy volunteer studies assessing safety, tolerability, and pharmacokinetics (PK), as well as radiolabeled formulations for human absorption, distribution, metabolism, and excretion (ADME) studies. Utilize our services as a standalone offering or as part of an integrated drug development program tailored to meet your needs.
-
Info SheetQuotient Sciences Aseptic Development & Manufacturing Capabilities Info SheetQuotient Sciences has expertise in developing, manufacturing, testing, releasing, and supplying a range of formulations (IV, SC, and IM administration) for a variety of clinical study types, including first-in-human (FIH) healthy volunteer studies assessing safety, tolerability, and pharmacokinetics (PK), as well as radiolabeled formulations for human absorption, distribution, metabolism, and excretion (ADME) studies.
-
Info SheetTranslational Pharmaceutics® Fact SheetQuotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.
-
WebinarUpcoming Webinar: Strategies for Achieving Regulatory Milestones FasterSave your spot for our next webinar featuring a customer case study from Ensysce Biosciences on April 19, 2023. Dr. Vanessa Zann, Senior Drug Development Consultant, will be joined by Lynn Kirkpatrick, CEO of Ensysce Biosciences for this special presentation.
-
WebinarUpcoming Webinar: Quotient Sciences and Charles River Collaboration WebinarJoin experts from Quotient Sciences & Charles River for a webinar taking place on 18 May, "Integrated Strategies for Accelerating from Discovery to IND and Beyond: Charles River & Quotient Sciences Collaboration."